Get the Stockscreener App
10.79
3.45%
0.36
Pre-market:
10.70
-0.09
-0.83%
Neuropace Inc stock is traded at $10.79, with a volume of 173.05K.
It is up +3.45% in the last 24 hours and down -4.00% over the past month.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
See More
Previous Close:
$10.43
Open:
$10.42
24h Volume:
173.05K
Relative Volume:
0.73
Market Cap:
$347.42M
Revenue:
$65.42M
Net Income/Loss:
$-32.96M
P/E Ratio:
-8.4961
EPS:
-1.27
Net Cash Flow:
$-19.87M
1W Performance:
+1.41%
1M Performance:
-4.00%
6M Performance:
+68.86%
1Y Performance:
-21.53%
1-Day Range:
$10.25
$10.95
1-Week Range:
$9.89
$11.51
52-Week Range:
$5.45
$15.11
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
10.79 | 347.42M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
NeuroPace, Inc. (NASDAQ:NPCE) Short Interest Update - MarketBeat
NeuroPace Inc (NPCE) Trading Down 3.19% on Apr 15 - GuruFocus
NeuroPace expects minimal tariff impact, maintains guidance By Investing.com - Investing.com South Africa
NeuroPace expects minimal impact of tariffs on its operations and financial results - MSN
Neuropace Provides Update On Tariff Status - marketscreener.com
NeuroPace Reports 'Minimal impact' From Trump Tariffs - MarketScreener
NeuroPace Expects Minimal Impact from Trade Tariffs - TipRanks
NeuroPace expects minimal tariff impact, maintains guidance - Investing.com
NeuroPace Provides Update on Tariff Status - The Manila Times
US Manufacturing Shield: NeuroPace Dodges Tariff Headwinds as Peers Struggle - Stock Titan
NeuroPace stock target cut to $17 by Cantor Fitzgerald - Investing.com Australia
What is Leerink Partnrs' Forecast for NeuroPace Q1 Earnings? - MarketBeat
Cantor Fitzgerald cuts NeuroPace stock target to $17 By Investing.com - Investing.com Canada
Cantor Fitzgerald cuts NeuroPace stock target to $17 - Investing.com
NeuroPace reports 82% seizure reduction in epilepsy study By Investing.com - Investing.com Australia
NeuroPace Reports Data From 3-year Post-Approval Study Of RNS System In Focal Epilepsy - Nasdaq
NeuroPace reports 82% seizure reduction in epilepsy study - Investing.com
NeuroPace announces data from long-term post-approval study of RNS System - TipRanks
NeuroPace Announces Data From a Long-Term Post-Approval - GlobeNewswire
Breakthrough: New Epilepsy Device Shows 82% Seizure Reduction, FDA Study Reveals - Stock Titan
NeuroPace, Inc. (NASDAQ:NPCE) Sees Large Growth in Short Interest - MarketBeat
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting - The Manila Times
Breakthrough Results: NeuroPace's Brain-Responsive Epilepsy Treatment Shows 3-Year Outcomes - Stock Titan
NeuroPace refocuses product portfolio; reaffirms 2025 revenue guidance - MSN
NeuroPace to end SEEG product distribution, maintains 2025 revenue outlook By Investing.com - Investing.com Canada
NeuroPace to End Stereo EEG Distribution Accord; 2025 Revenue Guidance Affirmed - MarketScreener
NeuroPace to terminate distribution relationship for Seeg products - TipRanks
NeuroPace Shifts Focus to Core RNS System - TipRanks
Neuropace Inc Maintaining 2025 Revenue Guidance - MarketScreener
NeuroPace to end SEEG product distribution, maintains 2025 revenue outlook - Investing.com
NeuroPace Announces Refocusing of Product Portfolio - The Manila Times
NeuroPace Strategic Pivot: Higher Margins, AI Innovation, and 20% Growth Target Ahead - Stock Titan
NeuroPace (NASDAQ:NPCE) Shares Down 4.3%Should You Sell? - MarketBeat
Where are the Opportunities in (NPCE) - news.stocktradersdaily.com
Bank of New York Mellon Corp Has $328,000 Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace (NASDAQ:NPCE) Stock Price Down 4.3% – What’s Next? - Defense World
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
NeuroPace Leadership Reveals Growth Strategy: Key Insights Coming at Needham Conference - Stock Titan
(NPCE) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Seed Treatment Market Top PlayersNeuropace, Inc., Biotronik, - openPR
Cantor Fitzgerald maintains Overweight on NeuroPace stock By Investing.com - Investing.com Australia
NeuroPace at attractive entry point, remains best idea, says Cantor Fitzgerald - TipRanks
Cantor Fitzgerald maintains Overweight on NeuroPace stock - Investing.com India
NeuroPace’s SWOT analysis: stock poised for growth amid expanding market By Investing.com - Investing.com Australia
NeuroPace’s SWOT analysis: stock poised for growth amid expanding market - Investing.com India
Analysts Set Expectations for NeuroPace FY2025 Earnings - MarketBeat
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neuropace Inc Stock (NPCE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
1.01%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):